Biotechnology UltraSector ProFund

The Biotechnology UltraSector ProFund seeks daily investment results, before fees and expenses, that are 1.5x the return of the Dow Jones U.S. BiotechnologySM Index (the "Index") for a single day.

View Prospectus

Fund Snapshot

Investor Class Service Class
CUSIP 743185480 743185472
Fund Number 043 073
Inception Date 6/19/2000
Fund Group Sector ProFunds - UltraSector

Fund Statistics

Limits On Exchanges None
Minimum Investment
Individual Investor $15,000
Financial Professionals $5,000

NAV as of 5/27/2016

Class NAV % Change $ Change
Investor $53.62 1.30% $0.69 NAV History
Service $44.33 1.30% $0.57 NAV History
BIPIX Current Quote and Chart

Returns (as of 3/31/2016)

Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost.

For standardized returns year-to-date, and as of the most recent calendar quarter-end, and annualized month-end, see performance. Returns include the reinvestment of dividends and capital gains.

YTD (as of 5/27/2016) -17.71%
Average Annual One Year -26.90%
Average Annual Three Year 21.84%
Average Annual Five Year 32.99%
Average Annual Ten Year 15.43%
Average Annual Since Inception 5.91%
Cumulative Since Inception 147.56%
Gross Expense Ratio 1.49%
Net Expense Ratio * 1.49%

* Contractual waiver effective from December 1, 2015 through November 30, 2016. Without such a waiver of fees, the total returns would have been lower.

All data, unless otherwise noted, is as of 3/31/2016 and for Investor Class Shares only and is subject to change.


Dow Jones U.S. Biotechnology Index

The Index (Bloomberg symbol: DJUSBT) measures the performance of the biotechnology sector of the U.S. equity market. Component companies engage in research and development of biological substances for drug discovery and diagnostic development. These companies derive most of their revenue from the sale or licensing of drugs and diagnostic tools. It is not possible to invest directly in an index.ex.

Total Index Companies 40
Price/Earnings Ratio 15.88
Price/Book Ratio 6.95
Dividend Yield 1.32%
Average Index Market Capitalization 18.08 billion

Index as of 3/31/2016

Index Sector Weightings Weight
Biotechnology 94.69%
Life Sciences Tools & Services 5.31%
Pharmaceuticals 0.00%

Index as of 3/31/2016

Top 10 Index Companies Weight
Gilead Sciences Inc. 17.94%
Amgen Inc. 16.11%
AbbVie Inc. 13.15%
Celgene Corp. 11.18%
Biogen Inc. 8.13%
Alexion Pharmaceuticals Inc. 4.48%
Regeneron Pharmaceuticals Inc. 4.02%
Baxalta Inc. 3.93%
Illumina Inc. 3.41%
Vertex Pharmaceuticals Inc. 2.80%